IMPG2

Across TCGA pan-cancer cohorts, IMPG2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IMPG2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher IMPG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IMPG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and ESCA show a favorable association.

CESC, SKCM, and UCEC are the cancer types where IMPG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.091	0.755	<.001	24	view →
SKCM	OS	Median	II,III,IV	0.122	0.326	.004	21	view →
UCEC	DFS	Median	All	0.955	0.826	.015	14	view →
ESCA	DFS	Median	II,III,IV	0.718	0.280	.017	13	view →
LIHC	DFS	Median	II,III,IV	0.090	0.429	.011	9	view →
HNSC	OS	Median	All	0.444	0.713	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IMPG2–CESC (OS)

Open the CESC breakdown →